Solitaire Revascularization Device

INDICATIONS

The Solitaire™ Revascularization Device is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should be started within 6 hours of symptom onset.

The Solitaire™ Revascularization Device is indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment.

Product Details

The Solitaire device is comprised of a nitinol scaffolding design attached to a pushwire. The Solitaire device is designed to be delivered through a micro catheter, deployed across a clot, and removed along with the clot to enable revascularization of the occluded intracranial vessel. 

Parametric Design

Unique^4,5 overlapping stent retriever-based design allows the device to expand in larger vessels and compress in smaller vessels during deployment and retrieval all while:

• Maintaining consistent cell size and structure⁴
• Limiting device elongation and foreshortening⁴
• Providing multiple planes of clot integration contact^4,5

Align, Visualize, Retrieve

Retaining the same effective Parametric design^3-5 as the original Solitaire FR and subsequent Solitaire 2 devices, the Solitaire Platinum devices are enhanced with distinctive evenly spaced platinum markers to provide improved visualization⁶ for accurate alignment and retrieval.

4x40

The 4x40 length device simplifies placement with proximal ophthalmic alignment providing complete coverage of the stroke zone from ICA to M2.²